Literature DB >> 21033252

BC047440 overexpression is a risk factor for tumor invasion and poor prognosis in hepatocellular carcinoma.

Lu Zheng1, XiaoBing Huang, Ping Liang, Yu Wen, TongHan Yang, Yan Li, HongZhi Zhao, KeQiang Han, Jing Li.   

Abstract

BACKGROUND/AIMS: The aim of this study was to investigate the relationship between a new tumor-relative protein (BC047440) expression and clinic pathological parameters of hepatocellular carcinoma (HCC), and to evaluate the prognostic value of BC047440 for HCC patients.
METHODS: Following the prokaryotic expression and polyclonal antibodies generation of BC047440, two methods, including western blot and immunohistochemical staining were employed to detect BC047440 expression in 68 HCC specimens. The correlation between BC047440 expression and clinicopathologic outcome, and prognostic value of BC047440 for HCC patients were analyzed.
RESULTS: The polyclonal antibodies could effectively recognize endogenous BC047440 in HCC tissues. Western blot and immunohistochemical staining revealed that the expression of BC047440 protein was higher in HCCs than that in adjacent tissues and normal liver tissues. Statistical analysis showed that there was a good correlation between BC047440 expression and tumor size and invasion of HCC. HCC patients with BC047440-positive expression showed a significantly poor prognosis than those with BC047440-negative expression.
CONCLUSIONS: BC047440 has a regulatory function in progress of HCC and it may become a helpful indicator in handling HCC treatment and judging invasion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21033252

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  3 in total

1.  BC047440 antisense eukaryotic expression vectors inhibited HepG2 cell proliferation and suppressed xenograft tumorigenicity.

Authors:  Lu Zheng; Ping Liang; JianBo Zhou; XiaoBing Huang; Yu Wen; Zheng Wang; Jing Li
Journal:  Braz J Med Biol Res       Date:  2012-01-12       Impact factor: 2.590

2.  ShRNA-targeted COMMD7 suppresses hepatocellular carcinoma growth.

Authors:  Lu Zheng; Ping Liang; Jing Li; Xiao-bing Huang; Shi-cheng Liu; Hong-zhi Zhao; Ke-qiang Han; Zheng Wang
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

3.  COMMD7 is correlated with a novel NF-κB positive feedback loop in hepatocellular carcinoma.

Authors:  Lu Zheng; Chang-Lin Deng; Liang Wang; Xiao-Bing Huang; Nan You; Yi-Chen Tang; Ke Wu; Ping Liang; Na Mi; Jing Li
Journal:  Oncotarget       Date:  2016-05-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.